The MelMarT-II Trial is investigating whether reducing the amount of skin removed during surgery can reduce the risk of associated long-term pain and improve quality of life without increasing the risk of melanoma returning.
Currently there is no high-quality evidence or consensus in the medical community about the optimal melanoma excision margin size for high-risk primary cutaneous melanoma.
The international clinical trial coordinated by MASC Trials is hoping to resolve this issue by investigating whether there is a difference in disease-free survival for patients treated with either a 1cm or 2cm excision margin for stage II primary cutaneous melanoma.
Almost 3,000 participants from around the world will join the trial, which is a phase III, multi-centre, multi-national randomised control trial.
Coordinated by Melanoma and Skin Cancer Trials Ltd in Australia, the trial is located across 26 international sites in Australia, New Zealand, United Kingdom, USA, Canada, The Netherlands and Sweden. Plans for establishing more trial sites are underway, including new sites in Ireland and Slovenia. All current actively recruiting sites are listed at the bottom of this page.